|Bid||101.00 x 800|
|Ask||160.00 x 800|
|Day's range||146.60 - 149.17|
|52-week range||117.64 - 189.00|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.
Jazz (JAZZ) delivered earnings and revenue surprises of -0.53% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.